Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen

Antimicrob Agents Chemother. 2006 Jun;50(6):2210-3. doi: 10.1128/AAC.01447-05.

Abstract

Among 16 human immunodeficiency virus-infected (subtype C) Batswana patients who failed nelfinavir (NFV)-containing regimens, the most prevalent mutation observed was D30N (54%), followed by L90M (31%). L89I, K20T/I, and E35D polymorphic changes were also identified. These findings suggest that subtype C viruses in Botswana may develop resistance to NFV via subtype-specific pathways.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution
  • CD4 Lymphocyte Count
  • Drug Resistance, Viral / genetics*
  • Genetic Variation
  • HIV Infections / drug therapy
  • HIV Infections / epidemiology
  • HIV Infections / virology*
  • HIV Protease Inhibitors / pharmacology*
  • HIV Protease Inhibitors / therapeutic use
  • HIV-1 / classification
  • HIV-1 / drug effects*
  • HIV-1 / genetics*
  • HIV-1 / isolation & purification
  • Humans
  • Mutation*
  • Nelfinavir / pharmacology*
  • Nelfinavir / therapeutic use
  • Phylogeny
  • Polymorphism, Genetic
  • Prevalence
  • RNA, Viral / chemistry
  • RNA, Viral / genetics
  • Selection, Genetic
  • Treatment Failure
  • Viral Load
  • Virus Replication / drug effects

Substances

  • HIV Protease Inhibitors
  • RNA, Viral
  • Nelfinavir